ANIKHealthcare · Drug Manufacturers - Specialty & GenericThe 2 Wall Street analysts covering Anika Therapeutics, Inc. hold a median 12-month price target of $21 — -0.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 12 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Anika Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (95): Sales and profits are climbing, and climbing faster than before.
Accruals (60): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ANIK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −0.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | B. Riley Securities | Maintains | Buy | $18 → $21 |
| 27 Feb 2026 | Barrington Research | Maintains | Outperform | $16 → $17 |
| 27 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 9 Jan 2026 | Barrington Research | Maintains | Outperform | — |
| 6 Nov 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 31 July 2025 | Barrington Research | Maintains | Outperform | — |
| 12 May 2025 | Barrington Research | Maintains | Outperform | — |
| 13 Mar 2025 | Barrington Research | Maintains | Outperform | — |
| 1 Nov 2024 | Barrington Research | Maintains | Outperform | — |
| 22 Oct 2024 | Barrington Research | Maintains | Outperform | — |
| 9 Aug 2024 | Barrington Research | Maintains | Outperform | — |
| 29 May 2024 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 9 May 2024 | Barrington Research | Maintains | Outperform | — |
| 14 Mar 2024 | Barrington Research | Maintains | Outperform | — |
| 14 Mar 2024 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 3 Jan 2024 | Barrington Research | Maintains | Outperform | — |
| 3 Nov 2023 | Barrington Research | Maintains | Outperform | — |
| 14 Aug 2023 | Barrington Research | Upgrade | Outperform | — |
| 10 Aug 2023 | Stephens & Co. | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANIK appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Anika Therapeutics, Inc. returned +143.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 49% of US stocks
Cheaper than 45% of US stocks
Cheaper than 3% of US stocks
Higher than 63% of US stocks
Higher than 53% of US stocks
Higher than 78% of US stocks
Higher than 66% of US stocks
Higher than 26% of US stocks
Higher than 42% of US stocks
Higher than 40% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Anika Therapeutics, Inc. has a market value of $281.2M and an enterprise value of $266.0M.
Revenue in the twelve months to 30 June 2026: $120.7M. The latest quarter grew 15.6% year on year.
Net income over the same four quarters: −$3.8M, a −3.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.27.
Free cash flow in the twelve months to 30 June 2026: $562K.
Anika Therapeutics, Inc. spent $15.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −27.4×; forward P/E: 22.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Anika Therapeutics, Inc. employs 235 people — $513K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Anika Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
On August 26th, 2026, Anika Therapeutics, Inc. (ANIK) was included in Zacks Investment Research's list of Zacks Rank #1 (Strong Buy) momentum stocks, alongside BTSG and OPHC.
Why it matters — For ANIK watchers, being named to Zacks' top momentum stock list is a notable external validation of the company's current market standing.
Zacks Investment Research highlighted Anika Therapeutics (ANIK) as a solid choice for shorter-term investors looking to capitalize on recent price trends, noting it passed the firm's shorter-term trading strategy-based screen.
Why it matters — The mention indicates that Anika's recent price trend, combined with its fundamental soundness, is being recognized by a stock-research screen.
Anika Therapeutics' stock has risen 43.4% over the past three months, driven by strong sales momentum and raised 2026 guidance. The company's pipeline is advancing with Cingal and Hyalofast, which have bolstered investor confidence.
Why it matters — ANIK watchers would care because the stock's significant gain, raised guidance, and pipeline progress signal strengthening company performance and growth prospects.
Zacks Investment Research highlighted five stocks showing strong recent price gains and earnings growth amid a market rally, including Anika Therapeutics (ANIK) alongside EDRY, OPHC, FET, and NESR.
Why it matters — This item signals that ANIK is being recognized for recent price strength and earnings growth, which may draw attention from investors tracking the stock.
Anika Therapeutics (ANIK) saw its stock price rise 11.10% over the past week, drawing attention from momentum investors evaluating the company's potential.
Why it matters — The significant one-week price gain may signal shifting investor sentiment or momentum around ANIK, which could interest current shareholders and potential watchers.
The 2 Wall Street analysts covering Anika Therapeutics, Inc. have a median 12-month price target of $21, with estimates ranging from $21 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Anika Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anika Therapeutics, Inc. 100 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Anika Therapeutics, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies -0.0% from the last close, and Ticker Nerd's factor model ranks Anika Therapeutics, Inc. 100 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Anika Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $21 over the next 12 months.
Anika Therapeutics, Inc. returned +143.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics.
The most recent item we track (Zacks Investment Research, 26 Aug 2026): "Best Momentum Stocks to Buy for August 26th". On August 26th, 2026, Anika Therapeutics, Inc. (ANIK) was included in Zacks Investment Research's list of Zacks Rank #1 (Strong Buy) momentum stocks, alongside BTSG and OPHC.
Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics. The company develops, manufactures, and commercializes hyaluronic acid-based products used in osteoarthritis pain management, regenerative medicine, sports medicine, and soft tissue repair. Its portfolio includes injectable therapies and orthopedic solutions designed to support mobility, tissue healing, and minimally invasive care for patients with degenerative joint conditions and musculoskeletal injuries. Anika Therapeutics serves healthcare professionals and clinical settings across the United States, Europe, and other international markets, with products used in orthopedics and related surgical applications. Headquartered in Bedford, Massachusetts, Anika Therapeutics Inc. plays a specialized role in the musculoskeletal care market by offering therapies and biomaterials that address joint health, cartilage repair, and recovery support.
CEO Mr. Stephen D. Griffin · 235 employees · United States · https://www.anika.com
